Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat PET/CT Imaging of Patients With Systemic Amyloidosis Using 124I-AT-01
NCT05968846Phase 2Completed
- Sponsor
- University of Tennessee Graduate School of Medicine
- Start
- Dec 2022
- Primary completion
- Aug 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of 124I-evuzamitide in systemic amyloidosis, sponsored by University of Tennessee Graduate School of Medicine. Started Dec 2022; status: completed.
02
Drugs
124I-evuzamitide
03
Conditions
systemic amyloidosis
Beyond the preview
Go deeper on NCT05968846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05968846.